A Phase 1b Study of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer - D4190C00006

Study identifier:D4190C00006

ClinicalTrials.gov identifier:NCT02000947

EudraCT identifier:2015-003715-38

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer

Medical condition

NSCLC

Phase

Phase 1

Healthy volunteers

No

Study drug

MEDI4736, Tremelimumab

Sex

All

Actual Enrollment

457

Study type

Interventional

Age

18 Years - 101 Years

Date

Study Start Date: 25 Oct 2013
Primary Completion Date: 17 Sept 2019
Study Completion Date: 17 Sept 2019

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2020 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria